Ladanyi, Marc

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 411

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 399

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research

Protein Kinase Regulation and GTPase SignalingColorectal Cancer Treatments and Studies

Cited by 290

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 274

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Lovly, C. M., McDonald, N. T., Chen, H., Ortiz-Cuaran, S., Heukamp, L. C., Yan, Y., Florin, A., Ozretić, L., Lim, D., Wang, L., et al. (2014) · Nature Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 268

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Yu, H. A., Suzawa, K., Jordan, E., Zehir, A., Ni, A., Kim, R., Kris, M. G., Hellmann, M. D., Li, B. T., Somwar, R., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 259

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 232

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 211

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Yu, H. A., Arcila, M. E., Hellmann, M. D., Kris, M. G., Ladanyi, M., & Riely, G. J. (2014) · Annals of Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 206

The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability

Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysSarcoma Diagnosis and Treatment

Cited by 193

Automated Real-World Data Integration Improves Cancer Outcome Prediction

Jee, J., Fong, C., Pichotta, K., Tran, T. N., Luthra, A., Waters, M., Fu, C., Altoe, M., Liu, S.-Y., Maron, S. B., et al. (2024) · Nature

Machine Learning in HealthcareCancer Genomics and Diagnostics

Cited by 188

RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

Yaeger, R., Cowell, E., Chou, J. F., Gewirtz, A. N., Borsu, L., Vakiani, E., Solit, D. B., Rosen, N., Capanu, M., Ladanyi, M., et al. (2015) · Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 187

Functional Copy-Number Alterations in Cancer

Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE

Genomic variations and chromosomal abnormalitiesCancer Genomics and Diagnostics

Cited by 170

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

Johnson, M. L., Sima, C. S., Chaft, J., Paik, P. K., Pao, W., Kris, M. G., Ladanyi, M., & Riely, G. J. (2013) · Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 166

Comprehensive pan-genomic characterization of adrenocortical carcinoma

Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell

Adrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Cited by 165

Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing

Cheng, D. T., Prasad, M., Chekaluk, Y., Benayed, R., Sadowska, J., Zehir, A., Syed, A., Wang, Y. E., Somar, J., Li, Y., et al. (2017) · BMC Medical Genomics

BRCA gene mutations in cancerGenomics and Rare Diseases

Cited by 158

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 150

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 149

Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations

Suehara, Y., Alex, D., Bowman, A., Middha, S., Zehir, A., Chakravarty, D., Wang, L., Jour, G., Nafa, K., Hayashi, T., et al. (2019) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 135

KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

Rekhtman, N., Ang, D. C., Riely, G. J., Ladanyi, M., & Moreira, A. L. (2013) · Modern Pathology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 117

Development of genome-derived tumor type prediction to inform clinical cancer care

Penson, A., Camacho, N., Zheng, Y., Varghese, A. M., Al-Ahmadie, H., Razavi, P., Chandarlapaty, S., Vallejo, C. E., Vakiani, E., Gilewski, T., et al. (2020) · JAMA Oncology

Cancer Genomics and DiagnosticsCancer Diagnosis and Treatment

Cited by 115

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

Eng, J., Woo, K. M., Sima, C. S., Plodkowski, A., Hellmann, M. D., Chaft, J. E., Kris, M. G., Arcila, M. E., Ladanyi, M., & Drilon, A. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 107

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 97

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition

Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 90